Vir Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vir Biotechnology, Inc.
Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.
Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.
- Large Molecule
- Other Names / Subsidiaries
- Humabs BioMed SA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.